Why did Pfizer report a loss in Q2 2026 when Adjusted EPS was $0.77?

The GAAP loss of $(0.04) per share reflects $4.3 billion in non-cash intangible asset impairments, mainly a $3.8 billion write-down of sigvotatug vedotin IPR&D after a Phase 3 lung cancer study did not show a statistically significant overall survival benefit versus docetaxel, plus a $525 million impairment on Oxbryta developed technology rights. Adjusted EPS excludes these items, along with amortization of intangibles, acquisition-related items, and certain legal charges, partly offset by a $1.9 billion gain from the ViiV Healthcare stake sale.

Is the revenue guidance raise a sign of broad-based strength?

Only partly. The $500 million midpoint increase is driven by about $1.5 billion of better-than-expected non-COVID product performance, which was partially offset by a roughly $1.0 billion reduction in COVID-19 product expectations. Reported Q2 operational growth was just 1%, and the company's growth figure excluding Comirnaty and Paxlovid was 5%, so the raise depends heavily on key growth brands like Eliquis, Padcev, and Lorbrena continuing to perform.

Does the Innovent deal change the earnings outlook?

Yes, modestly. Pfizer will record a $650 million acquired IPR&D charge in Q3 2026, which is expected to reduce Adjusted diluted EPS by about $0.10. Management reaffirmed the $2.80-$3.00 EPS range, so the deal is absorbed within guidance. In exchange, Pfizer gains rights to 12 early-stage cancer programs, though Innovent is eligible for up to $9.85 billion in milestones and royalties on approved products.

What are the implications of the CFO transition and the cost savings expansion?

The CFO transition is a near-term governance focus: Dave Denton leaves August 15, 2026, and Cecile Guegan (currently SVP Finance for the Global Biopharmaceutical Business) becomes Interim CFO on August 16 while the company searches externally. The expanded cost programs add roughly $2.5 billion of productivity savings from 2027-2029, but they carry about $6.0 billion of one-time costs, mostly cash for severance, implementation, and asset write-downs. Investors should weigh those charges against the savings timeline, which is subject to execution risk.

What is Pfizer's capital allocation posture after this quarter?

Pfizer is prioritizing reinvestment in R&D ($5.3 billion in the first half), business development, and dividends ($4.9 billion, or $0.86 per share, in the first half), while focusing on de-leveraging. No share repurchases have been made in 2026, and guidance assumes none, even though $3.3 billion of authorization remains. Management has indicated that buybacks could resume in the future only after the balance sheet is de-levered.

PFE 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed August 4, 2026. Cited figures are marked; the original filing is the authoritative source.

Pfizer reported second-quarter 2026 results on August 4, 2026, showing revenues of $15.0 billion^a, up 3% reported and 1% operationally, with Adjusted diluted EPS of $0.77 (flat year over year).

Growth was narrow: excluding Comirnaty and Paxlovid, revenues rose 5% operationally, and products the company classifies as Launched and Acquired grew 18%. Reported results were a loss of $(0.04) per share, driven by $4.3 billion^b in non-cash intangible asset impairments (chiefly $3.8 billion on sigvotatug vedotin's Phase 3 lung cancer IPR&D asset after unfavorable trial results, and $525 million on Oxbryta) and a $1.9 billion gain from selling the ViiV Healthcare stake, which was offset by higher legal charges. Management raised the midpoint of full-year 2026 revenue guidance by $500 million to $60.5-$62.5 billion, citing about $1.5 billion of better-than-expected non-COVID performance, partly offset by a cut in COVID-19 product revenue expectations to about $4 billion from $5 billion.

Adjusted diluted EPS guidance of $2.80^c-$3.00 was reaffirmed, but it absorbs roughly $0.10 from a $650 million acquired IPR&D charge tied to the Innovent Biologics licensing deal, which closed July 10, 2026 and will be recorded in Q3 2026. The company also expanded its cost programs with about $2.5 billion of additional net savings expected from 2027 through 2029, against roughly $2.0 billion of one-time costs for the cost realignment initiative, and an additional $1.5 billion of COGS savings with about $4.0 billion in one-time costs. Total net savings targets now reach about $6.7 billion (cost realignment) and $3.0 billion (manufacturing optimization).

Leadership changes and capital allocation are also in focus. CFO Dave Denton departs August 15, 2026, and Cecile Guegan becomes Interim CFO on August 16 during a search for a permanent successor.

Pfizer paid $4.9 billion^d in dividends ($0.86 per share) in the first half and made no share repurchases in 2026, with $3.3 billion of authorization remaining. Management said it is prioritizing reinvestment and de-leveraging, and the guidance assumes no buybacks.

02—Key points

Key Highlights

Q2 2026 revenues of $15.0 billion, up 3% reported and 1% operationally; ex-Comirnaty and Paxlovid, operational growth was 5%.
Launched and Acquired Products grew 18% operationally, led by Padcev (+23%), Lorbrena (+37%), and Eliquis (+19%), while Paxlovid (-95%) and Comirnaty (-34%) declined sharply.
Reported Q2 loss of $(0.04) per share included $4.3 billion in non-cash intangible asset impairments, mainly the $3.8 billion sigvotatug vedotin IPR&D write-down after the Phase 3 SigVie-002 lung cancer study missed its overall survival endpoint.
Full-year 2026 revenue guidance raised $500 million at the midpoint to $60.5-$62.5 billion; COVID-19 revenue expectation lowered to about $4 billion from $5 billion.
Adjusted diluted EPS guidance of $2.80-$3.00 reaffirmed, but absorbs roughly $0.10 from the $650 million Innovent Biologics acquired IPR&D charge to be recorded in Q3 2026.
Announced additional cost savings: about $2.5 billion of productivity savings from 2027-2029 (about $1.0 billion SI&A plus $1.5 billion COGS), with total program targets of about $6.7 billion and $3.0 billion respectively and roughly $6.0 billion in one-time costs.
CFO Dave Denton departs August 15, 2026; Cecile Guegan named Interim CFO effective August 16 while a permanent search proceeds. No 2026 share repurchases are included in guidance.

03—Questions

Frequently Asked Questions

Why did Pfizer report a loss in Q2 2026 when Adjusted EPS was $0.77?
The GAAP loss of $(0.04) per share reflects $4.3 billion in non-cash intangible asset impairments, mainly a $3.8 billion write-down of sigvotatug vedotin IPR&D after a Phase 3 lung cancer study did not show a statistically significant overall survival benefit versus docetaxel, plus a $525 million impairment on Oxbryta developed technology rights. Adjusted EPS excludes these items, along with amortization of intangibles, acquisition-related items, and certain legal charges, partly offset by a $1.9 billion gain from the ViiV Healthcare stake sale.
Is the revenue guidance raise a sign of broad-based strength?
Only partly. The $500 million midpoint increase is driven by about $1.5 billion of better-than-expected non-COVID product performance, which was partially offset by a roughly $1.0 billion reduction in COVID-19 product expectations. Reported Q2 operational growth was just 1%, and the company's growth figure excluding Comirnaty and Paxlovid was 5%, so the raise depends heavily on key growth brands like Eliquis, Padcev, and Lorbrena continuing to perform.
Does the Innovent deal change the earnings outlook?
Yes, modestly. Pfizer will record a $650 million acquired IPR&D charge in Q3 2026, which is expected to reduce Adjusted diluted EPS by about $0.10. Management reaffirmed the $2.80-$3.00 EPS range, so the deal is absorbed within guidance. In exchange, Pfizer gains rights to 12 early-stage cancer programs, though Innovent is eligible for up to $9.85 billion in milestones and royalties on approved products.
What are the implications of the CFO transition and the cost savings expansion?
The CFO transition is a near-term governance focus: Dave Denton leaves August 15, 2026, and Cecile Guegan (currently SVP Finance for the Global Biopharmaceutical Business) becomes Interim CFO on August 16 while the company searches externally. The expanded cost programs add roughly $2.5 billion of productivity savings from 2027-2029, but they carry about $6.0 billion of one-time costs, mostly cash for severance, implementation, and asset write-downs. Investors should weigh those charges against the savings timeline, which is subject to execution risk.
What is Pfizer's capital allocation posture after this quarter?
Pfizer is prioritizing reinvestment in R&D ($5.3 billion in the first half), business development, and dividends ($4.9 billion, or $0.86 per share, in the first half), while focusing on de-leveraging. No share repurchases have been made in 2026, and guidance assumes none, even though $3.3 billion of authorization remains. Management has indicated that buybacks could resume in the future only after the balance sheet is de-levered.

04—Continue

← View all 8-K filings